- Home
- ELBM vs PRPO Comparison
ELBM vs PRPO Comparison
Compare ELBM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- PRPO
- Stock Information
- Founded
- ELBM 2011
- PRPO N/A
- Country
- ELBM Canada
- PRPO United States
- Employees
- ELBM N/A
- PRPO N/A
- Industry
- ELBM Industrial Machinery/Components
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ELBM Miscellaneous
- PRPO Industrials
- Exchange
- ELBM Nasdaq
- PRPO Nasdaq
- Market Cap
- ELBM 19.2M
- PRPO 22.0M
- IPO Year
- ELBM N/A
- PRPO N/A
- Fundamental
- Price
- ELBM $1.11
- PRPO $18.40
- Analyst Decision
- ELBM Strong Buy
- PRPO
- Analyst Count
- ELBM 2
- PRPO 0
- Target Price
- ELBM $2.20
- PRPO N/A
- AVG Volume (30 Days)
- ELBM 2.7M
- PRPO 22.5K
- Earning Date
- ELBM 11-14-2025
- PRPO 11-05-2025
- Dividend Yield
- ELBM N/A
- PRPO N/A
- EPS Growth
- ELBM N/A
- PRPO N/A
- EPS
- ELBM N/A
- PRPO N/A
- Revenue
- ELBM N/A
- PRPO $21,242,000.00
- Revenue This Year
- ELBM N/A
- PRPO N/A
- Revenue Next Year
- ELBM N/A
- PRPO N/A
- P/E Ratio
- ELBM N/A
- PRPO N/A
- Revenue Growth
- ELBM N/A
- PRPO 27.05
- 52 Week Low
- ELBM $0.77
- PRPO $3.90
- 52 Week High
- ELBM $2.60
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- ELBM 61.53
- PRPO 57.66
- Support Level
- ELBM $0.98
- PRPO $16.50
- Resistance Level
- ELBM $1.28
- PRPO $18.97
- Average True Range (ATR)
- ELBM 0.15
- PRPO 1.35
- MACD
- ELBM 0.02
- PRPO -0.21
- Stochastic Oscillator
- ELBM 60.78
- PRPO 46.22
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.